Page last updated: 2024-11-02

pioglitazone and Anemia

pioglitazone has been researched along with Anemia in 3 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"Pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, and a decrease in inflammatory markers, thus improving the risk factors of cardiovascular disease."9.14Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. ( Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2010)
"Pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, and a decrease in inflammatory markers, thus improving the risk factors of cardiovascular disease."5.14Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. ( Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2010)
"To investigate the recovery of thiazolidinedione-induced body weight gain and haematopoietic changes after stopping pioglitazone treatment in patients with Type 2 diabetes."3.80Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes. ( Chen, BK; Feng, CC; Lee, MY; Lin, KD; Shin, SJ; Yu, ML, 2014)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, KD1
Lee, MY1
Feng, CC1
Chen, BK1
Yu, ML1
Shin, SJ1
Barthel, A1
Abe, M1
Okada, K1
Maruyama, T1
Maruyama, N1
Soma, M1
Matsumoto, K1

Trials

1 trial available for pioglitazone and Anemia

ArticleYear
Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10

    Topics: Adiponectin; Adult; Aged; Anemia; Blood Pressure; C-Reactive Protein; Calcitriol; Diabetes Mellitus,

2010

Other Studies

2 other studies available for pioglitazone and Anemia

ArticleYear
Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:11

    Topics: Aged; Anemia; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Drug Monitoring; Erythrocy

2014
[Is Pioglitazone blessing or curse?].
    Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:17

    Topics: Anemia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Th

2016